Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

Franklin C(2017)Immunotherapy in melanoma: recent advances and future directions Eur J Surg Oncol 43 604-611

Livingstone E(2016)Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial Lancet Oncol 17 1558-1568

Roesch A(2016)Immune-related adverse events associated with immune checkpoint inhibitors BioDrugs 30 571-584

Schilling B(2015)Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 23-34

Schadendorf D(2016)Toxicity management of immunotherapy for patients with metastatic melanoma Ann Transl Med 4 272-1855

Hodi FS(2016)Prolonged survival in stage iii melanoma with ipilimumab adjuvant therapy N Engl J Med 375 1845-e551

Chesney J(2017)Adjuvant nivolumab versus ipilimumab in resected stage iii or iv melanoma N Engl J Med 17 e542-11924

Pavlick AC(2016)Predictive biomarkers for checkpoint inhibitor-based immunotherapy Lancet Oncol 8 592-574

Robert C(2017)Predictors of responses to immune checkpoint blockade in advanced melanoma Nat Commun 11 75-1206

Grossmann KF(2013)Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events J Transl Med 113 11919-43

Franklin C(2017)Immunotherapy in melanoma: recent advances and future directions Eur J Surg Oncol 43 604-611

Livingstone E(2016)Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial Lancet Oncol 17 1558-1568

Roesch A(2016)Immune-related adverse events associated with immune checkpoint inhibitors BioDrugs 30 571-584

Schilling B(2015)Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 23-34

Schadendorf D(2016)Toxicity management of immunotherapy for patients with metastatic melanoma Ann Transl Med 4 272-1855

Hodi FS(2016)Prolonged survival in stage iii melanoma with ipilimumab adjuvant therapy N Engl J Med 375 1845-e551

Chesney J(2017)Adjuvant nivolumab versus ipilimumab in resected stage iii or iv melanoma N Engl J Med 17 e542-11924

Pavlick AC(2016)Predictive biomarkers for checkpoint inhibitor-based immunotherapy Lancet Oncol 8 592-574

Robert C(2017)Predictors of responses to immune checkpoint blockade in advanced melanoma Nat Commun 11 75-1206

Grossmann KF(2013)Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events J Transl Med 113 11919-43